[Definitions](index=4&type=section&id=Section%201.%20Definitions) This chapter defines key terms, company abbreviations, partners, and regulatory bodies used in the report, providing a foundational understanding of its content - The chapter provides definitions for specialized terms, company abbreviations, partners, and regulatory bodies used throughout the report[9](index=9&type=chunk)[10](index=10&type=chunk) [Company Profile and Key Financial Indicators](index=5&type=section&id=Section%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Basic Information](index=5&type=section&id=Company%20Information) This chapter outlines the company's basic business registration, contact details, disclosure channels, and stock overview, clarifying its legal entity and investor communication pathways - The company's full name is Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., with stock abbreviation 'King-Friend' and stock code **603707**, listed on the Shanghai Stock Exchange[11](index=11&type=chunk)[15](index=15&type=chunk) [Key Financial Data and Indicators for the Past Three Years](index=6&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators%20for%20the%20Past%20Three%20Years) In 2020, the company achieved robust financial growth, with operating revenue up **18.03%** and net profit attributable to shareholders up **33.25%**, total assets expanded by **52.02%**, and profitability metrics significantly improved Key Accounting Data for the Past Three Years (Unit: CNY) | Key Accounting Data | 2020 | 2019 | YoY Change (%) | 2018 | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 2,914,880,930.50 | 2,469,669,305.11 | 18.03 | 1,700,330,667.14 | | Net Profit Attributable to Shareholders of Listed Company | 806,122,185.11 | 604,961,604.92 | 33.25 | 424,549,136.66 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 767,277,360.29 | 587,364,048.60 | 30.63 | 411,166,740.79 | | Net Cash Flow from Operating Activities | -565,848,347.40 | -841,381,294.60 | 32.75 | 62,368,493.94 | | **Asset Status** | **End of 2020** | **End of 2019** | **Period-end YoY Change (%)** | **End of 2018** | | Net Assets Attributable to Shareholders of Listed Company | 3,722,438,519.79 | 2,966,492,802.68 | 25.48 | 2,421,112,751.62 | | Total Assets | 7,720,360,460.30 | 5,078,419,276.66 | 52.02 | 3,402,323,291.73 | Key Financial Indicators for the Past Three Years | Key Financial Indicators | 2020 | 2019 | YoY Change (%) | 2018 | | :--- | :--- | :--- | :--- | :--- | | Basic EPS (CNY/share) | 0.86 | 0.65 | 32.31 | 0.45 | | Diluted EPS (CNY/share) | 0.87 | 0.65 | 33.85 | 0.46 | | Weighted Average ROE (%) | 24.46 | 22.52 | Increased by 1.94 percentage points | 19.12 | - In 2020, net cash flow from operating activities remained negative but improved by **32.75%** compared to 2019, primarily due to decreased raw material purchases, with the negative balance mainly influenced by increased accounts receivable from expanded preparation sales and higher inventory levels[18](index=18&type=chunk) [Quarterly Key Financial Data for 2020](index=7&type=section&id=Quarterly%20Key%20Financial%20Data%20for%202020) The company's 2020 quarterly operating revenue and net profit attributable to shareholders remained relatively stable, though net cash flow from operating activities was negative for the first three quarters, slightly improving in Q4, reflecting full-year business expansion-driven capital pressure Quarterly Key Financial Data for 2020 (Unit: CNY) | Indicator | Q1 | Q2 | Q3 | Q4 | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 734,151,941.80 | 661,668,655.98 | 762,549,427.40 | 756,510,905.32 | | Net Profit Attributable to Shareholders of Listed Company | 204,403,725.60 | 204,071,041.01 | 204,650,846.41 | 192,996,572.09 | | Net Cash Flow from Operating Activities | -90,491,766.00 | -229,168,679.05 | -242,453,881.92 | -3,734,020.43 | [Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) In 2020, the company's total non-recurring gains and losses amounted to **CNY 38.84 million**, primarily from government subsidies and investment income, a significant increase from **CNY 17.60 million** in 2019 Non-Recurring Gains and Losses Items (Unit: CNY) | Non-Recurring Gains and Losses Item | 2020 Amount | 2019 Amount | 2018 Amount | | :--- | :--- | :--- | :--- | | Government Subsidies | 37,967,430.46 | 12,738,908.38 | 6,882,125.08 | | Transactional Financial Assets Related Gains and Losses | 8,150,774.77 | 7,741,535.91 | 8,225,853.80 | | **Total** | **38,844,824.82** | **17,597,556.32** | **13,382,395.87** | [Company Business Overview](index=10&type=section&id=Section%203.%20Company%20Business%20Overview) [Main Business, Operating Model, and Industry Overview](index=10&type=section&id=Main%20Business%2C%20Operating%20Model%2C%20and%20Industry%20Overview) The company's core business spans R&D, production, and sales of full-range heparin products, anti-tumor, and other sterile injectables, alongside CDMO services, with rapid growth in high-end overseas preparations, particularly in the US market, establishing it as a leading Chinese injectable exporter - The company's core business strategy involves a full-industry chain layout based on heparin products, expanding into high-value sterile injectables (e.g., anti-tumor drugs) and CDMO services[26](index=26&type=chunk) - The company is a leading domestic injectable exporter, possessing four US FDA-certified production lines, with preparation export business accounting for over **50%** of its total preparation business[36](index=36&type=chunk) - The company is one of the world's major high-quality heparin API suppliers, having established long-term stable cooperative relationships with international mainstream preparation enterprises such as Pfizer and Sanofi[37](index=37&type=chunk)[46](index=46&type=chunk) - 2020 performance growth was primarily driven by the commercialization of R&D achievements, explosive growth in overseas preparation sales (US subsidiary Meitheal's revenue increased by **785.53%**), steady growth in domestic preparation business (**25%**), and high gross margins in the API business (benefiting from strategic inventory)[39](index=39&type=chunk)[41](index=41&type=chunk) [Core Competitiveness Analysis](index=16&type=section&id=Core%20Competitiveness%20Analysis) The company's core competitiveness lies in R&D and registration, market sales, production quality, customer resources, procurement, and integrated supply chain, boasting FDA-certified R&D, efficient global filing capabilities, a strong US sales network via Meitheal, advanced manufacturing technology, and strategic raw material procurement - **R&D and Registration Advantage**: The company possesses an FDA-certified R&D center, with an average of **10** ANDA approvals per year over the past three years, ranking as the top Chinese enterprise in terms of R&D approval speed in the US[42](index=42&type=chunk) - **Market and Sales Advantage**: Through the acquisition of US Meitheal, the company established localized marketing channels, directly engaging major purchasers like GPOs and IDNs, achieving rapid expansion in the US market[43](index=43&type=chunk) - **Production and Quality Advantage**: The company operates four FDA-audited sterile preparation production lines, mastering high-end technologies like fully enclosed isolation, with a production management system meeting regulatory requirements of major global pharmaceutical markets[45](index=45&type=chunk) - **Procurement and Integration Advantage**: The company employs an innovative 'centralized elution' procurement model and has built strategic crude heparin inventory since 2015, effectively mitigating raw material price fluctuation risks, with a complete heparin API to preparation industry chain layout ensuring long-term stable profitability[47](index=47&type=chunk) [Management Discussion and Analysis of Operations](index=19&type=section&id=Section%204.%20Management%20Discussion%20and%20Analysis%20of%20Operations) [Overview of Operations](index=19&type=section&id=Overview%20of%20Operations) In 2020, the company achieved **CNY 2.915 billion** in operating revenue, up **18.03%**, and **CNY 797 million** in net profit, up **31.41%**, primarily driven by strong preparation business growth, which exceeded **50%** of revenue, with 14 US ANDA approvals and Meitheal's revenue surging **785.53%**, while effectively managing foreign exchange losses - In 2020, the company's preparation revenue share exceeded **50%** for the first time, becoming the primary driver of performance growth[50](index=50&type=chunk) - Significant R&D achievements include **14** US FDA ANDA approvals during the reporting period, making the company the Chinese domestic manufacturer with the most US injectable ANDAs[49](index=49&type=chunk) - US subsidiary Meitheal's sales revenue achieved substantial growth, increasing by **785.53%** compared to 2019, with operating revenue approaching **USD 100 million**[50](index=50&type=chunk) - The company's heparin and low molecular weight heparin preparations achieved a rapid market share of **20%** in the US within just one year of launch, with sales performance nearing **30 million units**[50](index=50&type=chunk) - Despite significant fluctuations in USD and EUR exchange rates, the company, through precise capital operations, limited full-year exchange losses to **CNY 1.66 million**, significantly below the industry average for comparable foreign trade revenue[51](index=51&type=chunk) [Analysis of Main Business](index=23&type=section&id=Analysis%20of%20Main%20Business) In 2020, the company's main business revenue reached **CNY 2.911 billion**, up **18%**, with preparation business revenue surging **93.48%** to **50.63%** of total, surpassing raw materials, while standard heparin raw material gross margin significantly increased by **14.39 percentage points** to **56.14%** despite a **14.42%** revenue decline, and foreign market gross margin improved due to economies of scale Main Business by Product (Unit: CNY) | By Product | Operating Revenue | Operating Cost | Gross Margin (%) | Operating Revenue YoY Change (%) | Operating Cost YoY Change (%) | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Standard Heparin API | 1,304,154,037.51 | 572,029,524.10 | 56.14 | -14.42 | -35.56 | Increased by 14.39 percentage points | | Preparations | 1,474,123,032.87 | 532,317,590.05 | 63.89 | 93.48 | 154.38 | Decreased by 8.65 percentage points | | CDMO and Others | 133,050,494.92 | 89,861,343.47 | 32.46 | -26.70 | -14.91 | Decreased by 9.36 percentage points | Main Business by Region (Unit: CNY) | By Region | Operating Revenue | Operating Cost | Gross Margin (%) | Operating Revenue YoY Change (%) | Operating Cost YoY Change (%) | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Domestic | 971,026,990.25 | 305,757,452.62 | 68.51 | 39.07 | 90.03 | Decreased by 10.97 percentage points | | International | 1,940,300,575.05 | 888,451,004.99 | 54.21 | 9.53 | -14.85 | Increased by 31.91 percentage points | Production and Sales Volume Analysis | Main Product | Unit | Production Volume | Sales Volume | Production Volume YoY Change (%) | Sales Volume YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | Standard Heparin API | 100 million units | 40,044.93 | 22,980.88 | -5.93 | -44.77 | | Preparations | 10,000 units | 6,872.98 | 5,982.68 | 101.53 | 114.09 | [Analysis of Assets and Liabilities](index=27&type=section&id=Analysis%20of%20Assets%20and%20Liabilities) As of year-end 2020, total assets reached **CNY 7.72 billion**, up **52.02%**, driven by a **36.15%** increase in inventory, a **1393.39%** surge in transactional financial assets, and a **101.37%** rise in accounts receivable due to sales growth, with short-term borrowings up **55.84%** to support business expansion, indicating a rapid growth phase Major Balance Sheet Items Change Analysis (Unit: CNY) | Item Name | Current Period-end Amount | Previous Period-end Amount | Change Ratio (%) | Main Reason | | :--- | :--- | :--- | :--- | :--- | | Transactional Financial Assets | 845,794,154.61 | 56,635,833.33 | 1,393.39 | Due to purchase of redeemable demand wealth management products | | Accounts Receivable | 783,312,186.00 | 388,990,075.28 | 101.37 | Due to sales growth | | Inventory | 4,457,423,902.01 | 3,273,856,779.15 | 36.15 | Due to increased raw material prices and higher inventory for overseas business expansion | | Short-term Borrowings | 2,132,430,038.42 | 1,368,366,370.23 | 55.84 | Due to increased short-term bank borrowings | [Analysis of Industry Operating Information](index=29&type=section&id=Analysis%20of%20Industry%20Operating%20Information) This chapter analyzes the pharmaceutical industry's policy environment, market conditions for key products, and R&D progress, highlighting national medical insurance negotiations and centralized drug procurement as key trends impacting industry profits and market structure, while the company's R&D investment grew **15.84%** to **CNY 221 million** in 2020, with 56 ongoing projects and 14 US ANDA approvals, demonstrating strong R&D and registration capabilities - Industry Trend: National medical insurance catalog negotiations and centralized drug procurement continue to advance, with price reduction as the main theme, accelerating industry innovation and market consolidation, benefiting leading enterprises[75](index=75&type=chunk) Key Products Approved for Listing During the Reporting Period | Product Name | Application Country | Approval Date | | :--- | :--- | :--- | | Doxercalciferol Injection | USA | 2020年2月7日 | | Heparin Sodium Injection | USA | 2020年2月24日 | | Bortezomib for Injection | USA | 2020年3月22日 | | Dalteparin Sodium Injection | China | 2020年5月26日 | | Busulfan Injection | USA | 2020年10月23日 | | Gemcitabine Hydrochloride Injection | USA | 2020年12月12日 | | Cisatracurium Besilate Injection | China | 2020年12月22日 | R&D Investment (Unit: CNY) | Item | Amount | | :--- | :--- | | Expensed R&D Investment for Current Period | 187,532,206.16 | | Capitalized R&D Investment for Current Period | 33,916,295.47 | | **Total R&D Investment** | **221,448,501.63** | | Total R&D Investment as % of Operating Revenue | 7.60 | | Number of R&D Personnel | 306 | | Proportion of Capitalized R&D Investment (%) | 15.32 | [Discussion and Analysis of Future Development](index=40&type=section&id=Discussion%20and%20Analysis%20of%20Future%20Development) The company anticipates continued growth in global heparin and anti-tumor markets, aiming to become a top-tier international biopharmaceutical enterprise by consolidating heparin leadership, diversifying product lines, and achieving vertical integration, with strategic plans including synchronized US-China R&D, strengthening raw material market position, building robust domestic sales, achieving overseas preparation sales breakthroughs via Meitheal, and ensuring successful fundraising project implementation, while acknowledging risks like policy changes, quality control, raw material prices, and market shifts - **Development Strategy**: Aspiring to be a 'first-class international biopharmaceutical enterprise,' consolidating heparin product advantages, expanding other pharmaceutical product lines, and achieving product diversification and vertical production integration[109](index=109&type=chunk) - **Operating Plan**: - **R&D**: Adhere to synchronized US-China R&D and dual-filing strategies, increase R&D investment, and establish an efficient R&D pace - **Marketing**: Build a strong marketing team, embrace centralized procurement policies, and leverage internet platforms to expand domestic market coverage - **Overseas**: Rely on US subsidiary Meitheal to achieve new breakthroughs in overseas preparation sales - **Capacity**: Advance convertible bond fundraising projects, construct high-end preparation production lines, and enhance high-end manufacturing capabilities[111](index=111&type=chunk)[112](index=112&type=chunk) - **Key Risks**: The company faces industry policy risks (e.g., centralized procurement, medical insurance cost control), product quality control risks, raw material (crude heparin) price increase risks, and risks from changes in the heparin preparation market landscape[114](index=114&type=chunk)[115](index=115&type=chunk)[116](index=116&type=chunk) [Significant Matters](index=44&type=section&id=Section%205.%20Significant%20Matters) [Profit Distribution and Dividends](index=44&type=section&id=Proposed%20Profit%20Distribution%20or%20Capital%20Reserve%20to%20Share%20Capital%20Plan%20for%20Common%20Shares) The company's 2020 profit distribution plan proposes a cash dividend of **CNY 1.5** (tax inclusive) and 3 bonus shares per 10 shares, continuing its three-year trend of cash dividends and capital increases, with 2020 cash dividends representing **17.38%** of net profit attributable to shareholders, compared to **35.63%** in 2019 - 2020 Profit Distribution Plan: A cash dividend of **CNY 1.5** (tax inclusive) and **3** bonus shares per **10** shares[5](index=5&type=chunk) Dividend Distribution Plans for the Past Three Years | Dividend Year | Bonus Shares per 10 Shares (shares) | Cash Dividend per 10 Shares (CNY) (tax incl.) | Capitalized Shares per 10 Shares (shares) | Cash Dividend Amount (CNY 10,000) | Ratio to Net Profit Attributable to Shareholders (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | 2020 | 3 | 1.5 | 0 | 14,012.41 | 17.38 | | 2019 | 0 | 3 | 3 | 21,557.45 | 35.63 | | 2018 | 0 | 1.5 | 3 | 8,290.09 | 19.53 | [Equity Incentive Plan](index=48&type=section&id=Company%20Equity%20Incentive%20Plan) During the reporting period, the company implemented its 2020 Restricted Stock Incentive Plan and completed partial unlocking of the 2018 plan, while also repurchasing and canceling some granted restricted shares due to employee departures or unmet performance targets - Disclosed the 'King-Friend 2020 Restricted Stock Incentive Plan (Draft),' proposing to grant no more than **227,000 shares**[129](index=129&type=chunk) - Completed the second unlocking of the initial grant and the first unlocking of the reserved portion of the 2018 Restricted Stock Incentive Plan, totaling **881,762 shares** listed for circulation[129](index=129&type=chunk) [Guarantees](index=51&type=section&id=Guarantees) During the reporting period, all external guarantees were for subsidiaries, with a total year-end guarantee balance of **CNY 321 million**, representing **8.58%** of the company's net assets, primarily supporting the operations and development of Hong Kong King-Friend, Meitheal, and Nanjing Jianzhi Ziming Total Company Guarantees | Item | Amount (CNY) | | :--- | :--- | | Total Guarantees to Subsidiaries During Reporting Period | 509,529,441.00 | | Total Guarantees to Subsidiaries at Period-end | 321,286,076.00 | | Total Guarantees as % of Company Net Assets (%) | 8.58 | [Convertible Corporate Bonds](index=60&type=section&id=Convertible%20Corporate%20Bonds) In 2020, the company successfully issued two convertible corporate bonds: 'King-Friend Convertible Bond' (**CNY 503 million**) and 'KF20 Convertible Bond' (**CNY 780 million**), with 'King-Friend Convertible Bond' listed in May 2020 and experiencing minor conversions, while its conversion price was adjusted due to equity incentives and profit distribution - On April 23, 2020, publicly issued 'King-Friend Convertible Bond' with a total amount of **CNY 503 million**, code **113579**[155](index=155&type=chunk) - On December 17, 2020, publicly issued 'KF20 Convertible Bond' with a total amount of **CNY 780 million**, code **113614**[157](index=157&type=chunk) - The conversion price of 'King-Friend Convertible Bond' was adjusted from an initial **CNY 54.97/share** to **CNY 42.05/share** due to the implementation of equity incentives and 2019 equity distribution[162](index=162&type=chunk) [Share Changes and Shareholder Information](index=63&type=section&id=Section%206.%20Common%20Share%20Changes%20and%20Shareholder%20Information) [Common Share Capital Changes](index=63&type=section&id=Common%20Share%20Capital%20Changes) During the reporting period, the company's total share capital increased from **718.47 million shares** to **934.16 million shares**, primarily due to the 2019 profit distribution plan (3 bonus shares per 10 shares), 2020 restricted stock grants, repurchase and cancellation of some restricted shares, and minor convertible bond conversions - The company's total share capital increased from **718.47 million shares** at the beginning of the period to **934.16 million shares** at the end of the period[165](index=165&type=chunk) - The primary reason for the increase in share capital was the transfer of **3** bonus shares per **10** shares from capital reserves to all shareholders, totaling **216 million shares**[166](index=166&type=chunk) [Shareholders and Actual Controllers](index=66&type=section&id=Shareholders%20and%20Actual%20Controllers) As of year-end 2020, the company had **19,017** shareholders, with the top three being Xie Juhua (**27.85%**), Jiangsu Coastal Development Group Co., Ltd. (**21.80%**), and TANG YONGQUN (**20.26%**), with Xie Juhua and TANG YONGQUN, mother and son, acting in concert as the actual controllers Top Ten Shareholders' Holdings | Shareholder Name | Shares Held at Period-end | Proportion (%) | | :--- | :--- | :--- | | Xie Juhua | 260,167,427 | 27.85 | | Jiangsu Coastal Development Group Co., Ltd. | 203,647,922 | 21.80 | | TANG YONGQUN | 189,281,212 | 20.26 | | Huang Xiwei | 41,807,229 | 4.48 | | Fullgoal Optimized Flexible Allocation Mixed Fund (LOF) | 19,190,346 | 2.05 | - The company's actual controllers are Xie Juhua, TANG YONGQUN (Tang Yongqun), and Ding Ying, with Xie Juhua and TANG YONGQUN being mother and son, having signed a concerted action agreement[175](index=175&type=chunk)[179](index=179&type=chunk)[182](index=182&type=chunk) [Directors, Supervisors, Senior Management, and Employees](index=72&type=section&id=Section%208.%20Directors%2C%20Supervisors%2C%20Senior%20Management%2C%20and%20Employees) [Holdings and Remuneration of Directors, Supervisors, and Senior Management](index=72&type=section&id=Changes%20in%20Holdings%20and%20Remuneration) During the reporting period, the company's core management maintained stable shareholdings, with changes primarily from the annual profit distribution plan; Chairman Tang Yongqun's total pre-tax remuneration was **CNY 1.5 million**, and Director and Deputy General Manager Huang Xiwei's was **CNY 1.11 million**, supported by a performance-linked compensation and assessment mechanism Core Management Remuneration (Unit: CNY 10,000) | Name | Position | Total Pre-tax Remuneration from Company During Reporting Period | | :--- | :--- | :--- | | Tang Yongqun | Chairman, General Manager | 150 | | Huang Xiwei | Director, Deputy General Manager, CFO, Board Secretary | 111 | | Wu Guiping | Deputy General Manager | 36.25 | [Employee Information](index=75&type=section&id=Employee%20Information) As of the reporting period end, the company and its main subsidiaries had **953** employees, with technical and production personnel comprising **38.6%** and **37.7%** respectively, and over **56%** holding bachelor's degrees or higher, reflecting the company's emphasis on high-caliber talent Employee Professional Composition | Professional Category | Number of People | | :--- | :--- | | Production Personnel | 359 | | Sales Personnel | 64 | | Technical Personnel | 368 | | Financial Personnel | 23 | | Administrative Personnel | 139 | | **Total** | **953** | Employee Education Level | Education Level Category | Number of People | | :--- | :--- | | PhD | 10 | | Master's | 74 | | Bachelor's | 454 | | Associate Degree | 262 | | Below Associate Degree | 153 | | **Total** | **953** | [Corporate Governance](index=76&type=section&id=Section%209.%20Corporate%20Governance) [Overview of Corporate Governance](index=76&type=section&id=Explanation%20of%20Corporate%20Governance%20Related%20Matters) During the reporting period, the company strictly adhered to laws and regulations like the Company Law and Securities Law, continuously improving its corporate governance structure, establishing and effectively implementing standardized systems for shareholders, board of directors, supervisory board, information disclosure, and investor relations, ensuring compliant and transparent operations while safeguarding all shareholders' interests - The company's governance structure is sound, operating strictly in accordance with relevant laws and regulations, ensuring the standardized operation of the general meeting of shareholders, board of directors, and supervisory board, and fulfilling information disclosure obligations truthfully, accurately, completely, and timely[199](index=199&type=chunk)[200](index=200&type=chunk) [Financial Report](index=80&type=section&id=Section%2011.%20Financial%20Report) [Audit Report](index=80&type=section&id=Audit%20Report) Zhongtianyun Certified Public Accountants (Special General Partnership) audited the company's 2020 financial statements, issuing a standard unqualified audit opinion, affirming that the financial statements fairly represent the company's financial position and operating results in all material respects, with 'revenue recognition' identified as a key audit matter due to its significance and rapid growth - The auditing firm is Zhongtianyun Certified Public Accountants (Special General Partnership), which issued a standard unqualified audit opinion[209](index=209&type=chunk)[210](index=210&type=chunk) - The key audit matter is 'revenue recognition,' for which auditors performed procedures including internal control testing, analytical procedures, contract examination, cut-off testing, and confirmations[212](index=212&type=chunk)[213](index=213&type=chunk)[214](index=214&type=chunk) [Financial Statements](index=83&type=section&id=Financial%20Statements) This chapter includes the company's 2020 consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, detailing the financial position at period-end, full-year operating results, and cash flow [Notes to Financial Statements](index=102&type=section&id=Notes%20to%20Financial%20Statements) Notes to the financial statements provide detailed explanations of financial statement items, including the company's basic information, basis of preparation, significant accounting policies and estimates, and specific notes on major consolidated financial statement items, indicating the company adopted new revenue standards from January 1, 2020, and disclosing related party transactions, share-based payments, and financial instrument risks - The company adopted the Ministry of Finance's revised 'Accounting Standard for Business Enterprises No. 14 – Revenue' starting January 1, 2020[323](index=323&type=chunk) - The company's revenue recognition principles are: domestic sales are recognized upon customer receipt, and export sales are recognized upon obtaining customs declaration forms[314](index=314&type=chunk) - The company faces primary financial risks including market risk (foreign exchange risk, interest rate risk), credit risk, and liquidity risk, and has implemented corresponding management and monitoring measures[487](index=487&type=chunk)[488](index=488&type=chunk) [Reference Documents Catalog](index=205&type=section&id=Section%2012.%20Reference%20Documents%20Catalog) - Reference documents include original financial statements bearing the signatures and seals of the legal representative, chief financial officer, and head of accounting, as well as the original audit report bearing the seal of the accounting firm and signatures and seals of certified public accountants[539](index=539&type=chunk)

Financial Performance - Net profit attributable to shareholders was ¥272,898,157.89, reflecting a growth of 33.51% year-on-year[7]. - Operating revenue for the period was ¥883,052,586.38, representing a 20.28% increase compared to the same period last year[7]. - Basic earnings per share increased by 31.82% to ¥0.29 from ¥0.22 in the previous year[7]. - The company reported a gross profit margin of approximately 57.5% for Q1 2021, compared to 31.6% in Q1 2020[25]. - The total comprehensive income for Q1 2021 was RMB 274,706,342.48, up from RMB 207,912,964.29 in Q1 2020, reflecting a growth of 32.0%[26]. - The net profit for Q1 2021 reached RMB 273,219,967.73, representing a 34.0% increase from RMB 204,019,285.30 in Q1 2020[26]. - The net profit for Q1 2021 reached CNY 324.33 million, up 63.5% from CNY 198.20 million in the same period last year[27]. Cash Flow - The net cash flow from operating activities was ¥6,147,710.84, a significant improvement from a negative cash flow of ¥90,491,766.00 in the previous year, marking a 106.79% increase[7]. - The total cash inflow from operating activities was CNY 960.82 million, compared to CNY 850.56 million in Q1 2020[30]. - In Q1 2021, the net cash flow from operating activities was CNY 331,473,067.30, a significant increase of 453.5% compared to CNY 59,756,565.97 in Q1 2020[32]. - The net cash flow from investing activities surged to ¥765,679,328.77, a 2,487.83% increase from ¥29,587,658.97 last year[16]. - The net cash flow from financing activities was CNY 587.25 million, compared to CNY 180.65 million in the same period last year[31]. - The total cash inflow from investment activities reached CNY 947,601,001.51, up from CNY 51,974,000.00 in the same period last year[32]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,639,548,208.22, an increase of 11.91% from the end of the previous year[7]. - The company's cash and cash equivalents increased to ¥1,507,039,674.57, up 205.34% from ¥493,553,116.59 in the previous period[13]. - Total liabilities increased to ¥4,616,013,103.15, up from ¥3,975,799,969.17, indicating a growth of around 16.1%[21]. - Current liabilities rose to ¥3,436,499,645.82 from ¥2,806,062,899.08, marking an increase of approximately 22.4%[20]. - The company's total liabilities as of Q1 2021 were RMB 3,949,029,163.04, a decrease from RMB 4,152,789,324.49 in the previous year[24]. - The company's equity attributable to shareholders increased to ¥4,000,496,422.62 from ¥3,722,438,519.79, representing a growth of approximately 7.5%[21]. Shareholder Information - The total number of shareholders at the end of the reporting period was 14,763[10]. - The top ten shareholders held a significant portion of shares, with the largest shareholder owning 27.85% of the total shares[10]. Expenses - The company reported a substantial increase in sales expenses, which rose by 58.88% to ¥120,735,651.53, attributed to higher sales volume[14]. - Research and development expenses for Q1 2021 were RMB 33,911,028.28, down from RMB 47,698,223.52 in Q1 2020, a decrease of 29.0%[25]. - Research and development expenses decreased to CNY 18.65 million, down 54.8% from CNY 41.27 million in Q1 2020[27]. Government Subsidies - The company received government subsidies amounting to ¥10,198,534.59, a 746.56% increase from ¥1,204,701.87 in the previous year[15]. - The company reported non-operating income of ¥9,231,233.39, primarily from government subsidies and other non-recurring gains[8][9]. Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[27].

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the first half of 2020, representing a year-on-year increase of 15%[9]. - The net profit attributable to shareholders was 300 million CNY, up 20% compared to the same period last year[9]. - The company's operating revenue for the first half of the year reached ¥1,395,820,597.78, an increase of 18.64% compared to ¥1,176,527,738.31 in the same period last year[16]. - Net profit attributable to shareholders was ¥408,474,766.61, reflecting a growth of 41.24% from ¥289,203,960.38 year-on-year[16]. - The net profit after deducting non-recurring gains and losses was ¥403,952,861.63, up 44.30% from ¥279,944,994.95 in the previous year[16]. - The company achieved revenue of CNY 1,395,820,597.78, representing a year-on-year growth of 18.64%[34]. - The net profit for the same period was CNY 406,822,200, reflecting a significant increase of 40.67% compared to the previous year[31]. - The total comprehensive income for the first half of 2020 was ¥410,772,049.17, compared to ¥289,565,755.99 in the same period of 2019, indicating a significant increase[124]. Research and Development - Research and development expenses increased by 30% year-on-year, totaling 150 million CNY, reflecting the company's commitment to innovation[9]. - The R&D investment for the reporting period was CNY 95,284,000, marking a year-on-year increase of 27.22%[33]. - Research and development expenses increased to ¥95,284,011.20, compared to ¥74,896,194.12 in the previous year, marking a rise of 27.25%[120]. - The company has registered over 40 products in the past three years, with an average of 10 new product applications annually[21]. - The company is actively pursuing CDMO collaborations to enhance R&D capabilities and improve production efficiency, thereby reducing costs[24]. Market Expansion and Strategy - The company plans to launch two new products in the second half of 2020, aiming for a 25% increase in market share[9]. - The company has established partnerships with three new distributors to expand its market reach in Southeast Asia[9]. - The company aims to enhance its international market share through the gradual release of production capacity from its IPO fundraising projects and previous convertible bond projects[22]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[9]. - The U.S. pharmaceutical market is a key focus, with the company planning to expand its sales scale by leveraging product quality and marketing capabilities[24]. Financial Position - The company's total assets increased by 23.35% to ¥6,264,108,775.03 from ¥5,078,419,276.66 at the end of the previous year[16]. - The company's total liabilities amounted to CNY 3,000,434,294.84, compared to CNY 2,074,325,056.24, which is an increase of 44.5%[117]. - The company's total owner's equity reached CNY 3,263,674,480.19, up from CNY 3,004,094,220.42, representing an increase of 8.6%[117]. - The company's cash and cash equivalents increased to CNY 743,173,405.23 from CNY 364,161,606.43, marking a significant increase of 104.4%[114]. - The company's total equity attributable to shareholders at the end of the reporting period was 3,226,281,539.81 CNY, leading to a net asset value per share of 4.49 CNY[100]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which may impact future performance[9]. - The company faces risks related to industry policy changes that could impact its operational model and competitive landscape[43]. - The company is exposed to foreign exchange risks due to a high proportion of revenue generated from exports settled in foreign currencies[50]. - The company faces risks related to international trade tensions, which could impact overseas sales if escalated[44]. - The pharmaceutical industry presents challenges in new product development, including high technical difficulty and long approval cycles[49]. Environmental and Compliance - The company is a key pollutant discharge unit in Nanjing, with no environmental pollution incidents or administrative penalties reported during the reporting period[83]. - The company has implemented a third-party monitoring system for wastewater, waste gas, and noise, with all pollution indicators meeting the discharge standards[90]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental protection authority[89]. - The company adheres to the national pollutant discharge standards, with specific limits set for various pollutants[93]. - The company maintains strict quality control standards to comply with cGMP regulations, essential for maintaining relationships with major partners like Pfizer and Sagent[45]. Shareholder and Corporate Governance - The company has committed that during their tenure, the transfer of shares will not exceed 25% of the total shares indirectly held by them each year[57]. - The company has appointed Zhongtianyun Accounting Firm as the auditor for the 2020 fiscal year, with a one-year term[60]. - The company has not engaged in any major related party transactions during the reporting period[64]. - The company maintains a stable shareholder structure with no changes in controlling shareholders[109]. - The total number of shares held by the company's directors and senior management remains at 384,119,075 shares[110]. Accounting and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial status and operational results[150]. - The company’s financial statements are prepared based on the principle of continuous operation, following relevant accounting standards and guidelines[148]. - The company recognizes loss provisions for financial instruments based on expected credit losses, which are measured at each balance sheet date[173]. - The company uses the effective interest method for subsequent measurement of financial assets measured at amortized cost, with gains or losses recognized in profit or loss upon derecognition or impairment[167]. - The company employs valuation techniques to determine the fair value of financial assets and liabilities, using inputs categorized into three levels based on market activity[170].

Financial Performance - The company's operating revenue for 2019 reached ¥2,469,669,305.11, representing a 45.25% increase compared to ¥1,700,330,667.14 in 2018[18]. - Net profit attributable to shareholders was ¥604,961,604.92 in 2019, up 42.50% from ¥424,549,136.66 in 2018[18]. - The total assets of the company increased by 49.26% to ¥5,078,419,276.66 at the end of 2019, compared to ¥3,402,323,291.73 at the end of 2018[18]. - Basic earnings per share rose to ¥0.84 in 2019, a 42.37% increase from ¥0.59 in 2018[19]. - The weighted average return on equity increased to 22.52% in 2019, up 3.40 percentage points from 19.12% in 2018[19]. - The company reported a net profit of ¥140,325,818.31 in Q2 2019, with Q3 and Q4 profits of ¥159,334,917.16 and ¥156,422,727.38 respectively[20]. - The company achieved total revenue of CNY 2,469,669,305.11, representing a year-on-year increase of 45.25%[41]. - The company reported a net profit of 604.96 million RMB for 2019, with a cash dividend amounting to 215.54 million RMB, representing 35.63% of the net profit[96]. Research and Development - R&D investment reached CNY 191,166,900, a 53.58% increase compared to the previous year, with a strong focus on anti-infection and anti-tumor drug development[40]. - The company has 65 ongoing R&D projects, with 28 projects already submitted for approval, focusing on high-demand therapeutic areas such as anti-infection and anti-tumor[63]. - The company has achieved significant growth in R&D investment, with some projects seeing increases of over 900% year-on-year[64]. - The R&D investment for the product P17D01 reached RMB 1,213.07 million, with a year-on-year increase of 921.27%[64]. - The R&D investment for the product P18D01 was RMB 677.34 million, showing a significant increase of 1,178.97% compared to the previous year[64]. Market Expansion and Strategy - The company aims to build a first-class international biopharmaceutical enterprise, focusing on high-quality heparin products and vertical integration[25]. - The company acquired Meitheal in the US to establish a marketing base, aiming to expand its presence in the US pharmaceutical market[28]. - The company is actively collaborating with local agents and pharmaceutical companies to penetrate non-US and non-China markets[28]. - The company aims to expand its market share in the US by leveraging its product quality and marketing capabilities[28]. - The company plans to expand its product offerings in the US market, focusing on long-lifecycle products that meet local demand in categories such as oncology and anticoagulation[79]. Financial Health and Liabilities - The total liabilities rose from 981.21 million RMB to 2,074.33 million RMB, leading to an increase in the debt-to-asset ratio from 28.84% to 40.85%[135]. - Short-term borrowings increased to ¥1,368,366,370.23, accounting for 26.94% of total liabilities, marking a 327.69% increase from the previous year[53]. - The company reported a significant increase in accounts receivable, which rose to CNY 388,990,075.28 from CNY 176,045,699.29, a growth of 120.4%[187]. - The company’s asset-liability ratio is reasonable, and it plans to repay the convertible bonds through stock conversion or cash flow from operations[128]. Environmental Compliance - The company is classified as a key pollutant discharge unit in Nanjing, emphasizing its commitment to environmental protection and compliance with regulations[114]. - The company has implemented a wastewater treatment facility with a daily capacity of approximately 400 tons, ensuring proper waste management[118]. - The company conducted third-party monitoring of wastewater and air emissions, confirming that all pollution indicators meet the required standards[121]. - The company has established an emergency response plan for environmental incidents, which has been filed with the Nanjing High-tech Zone Environmental Protection Bureau[120]. Corporate Governance - The company has not disclosed any significant related party transactions during the reporting period[106]. - The company confirmed that there were no significant defects in internal control during the reporting period[175]. - The company has implemented governance practices in accordance with relevant laws and regulations, ensuring shareholder rights and information symmetry[167]. - The company has established a remuneration and assessment committee responsible for formulating remuneration policies and evaluating the performance of directors and senior management[174]. Shareholder Information - The company has committed to not transferring or repurchasing shares held by major shareholders for 36 months post-IPO[97]. - The total number of shares held by the chairman and general manager, Tang Yongqun, increased by 33.6 million shares, resulting in a total of 145.6 million shares by year-end[151]. - The company reported a significant increase in shareholder engagement, as evidenced by the rise in the number of shareholders and the distribution of shares among major stakeholders[136]. - The company has implemented a stock incentive plan, with a total of 474,000 shares granted as part of the 2018 equity incentive plan[135].

Financial Performance - Net profit attributable to shareholders rose by 37.30% to CNY 204,403,725.60 year-on-year[4] - Operating revenue grew by 20.35% to CNY 734,151,941.80 compared to the same period last year[4] - Basic earnings per share increased by 33.33% to CNY 0.28[4] - The weighted average return on equity rose to 6.65%, an increase of 0.69 percentage points[4] - The net profit for Q1 2020 was CNY 204,019,285.30, compared to CNY 148,878,142.07 in Q1 2019, reflecting a year-over-year increase of about 36.9%[22] - The company reported a total comprehensive income of CNY 207,912,964.29 for Q1 2020, compared to CNY 148,215,207.16 in Q1 2019, an increase of approximately 40%[23] - The net profit for Q1 2020 reached CNY 198,201,860.36, up 60% from CNY 123,851,301.53 in the same period last year[25] - The company reported a total profit of CNY 228,167,583.13 for Q1 2020, compared to CNY 140,467,820.40 in Q1 2019, reflecting strong operational performance[25] Assets and Liabilities - Total assets increased by 6.04% to CNY 5,385,408,851.17 compared to the end of the previous year[4] - Total current assets increased to CNY 4,606,037,834.65 from CNY 4,288,776,008.47, representing a growth of approximately 7.4% year-over-year[16] - Total liabilities amounted to CNY 2,170,603,078.08, compared to CNY 2,074,325,056.24, reflecting an increase of approximately 4.7%[17] - The total equity attributable to shareholders increased to CNY 3,176,064,794.72 from CNY 2,966,492,802.68, representing a growth of approximately 7.1%[17] - The company's total liabilities rose to CNY 2,177,660,274.72 from CNY 2,165,960,270.60, showing a slight increase of about 0.54%[20] Cash Flow - Net cash flow from operating activities improved by 51.80%, reaching CNY -90,491,766.00[4] - The cash flow from operating activities showed a net outflow of CNY -90,491,766.00, an improvement from CNY -187,730,316.52 in Q1 2019[27] - Cash inflow from financing activities was CNY 774,165,946.50, compared to CNY 313,167,576.75 in Q1 2019, showing strong capital raising efforts[28] - The cash inflow from financing activities was ¥678,197,574.00, compared to ¥313,167,576.75 in Q1 2019, marking an increase of approximately 116.5%[30] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,603[7] - The largest shareholder, Jiangsu Coastal Development Group, holds 27.85% of shares[7] Investment and Expenses - R&D expenses grew by 31.14% to ¥47,698,223.52, reflecting continued investment in research and development[11] - Management expenses increased by 426.78% to ¥41,853,240.66, mainly due to the management costs of newly acquired subsidiaries[11] - Long-term equity investments surged by 209.65% to ¥2,898,539.44, attributed to increased investment income from PEKO[10] - The company incurred financial expenses of CNY 11,381,812.92, with interest expenses accounting for CNY 10,506,883.78, indicating increased borrowing costs[24] Current Assets and Liabilities - Cash and cash equivalents increased by 31.92% to ¥480,394,685.32 from ¥364,161,606.43[9] - The company's cash and cash equivalents increased to CNY 330,555,722.06 from CNY 178,978,788.32, marking an increase of 84.6%[18] - Inventory levels rose to CNY 3,255,355,911.46 from CNY 3,142,300,295.41, which is an increase of about 3.6%[18] - Other current liabilities rose dramatically by 2,075.48% to ¥42,371,769.78, mainly due to new payable expenses from the consolidation of a U.S. subsidiary[10] - The company’s other current liabilities increased significantly to CNY 42,371,769.78 from CNY 1,947,693.84, a rise of over 2000%[17]

Group 1: Company Overview and Business Strategy - Jianyou Co., Ltd. focuses on heparin as its main business, integrating production, research and development, and sales, with a vision to establish an internationally leading pharmaceutical enterprise [2] - The company's business modules are divided into four segments: heparin raw materials, heparin preparations, generic drugs - sterile preparations, and CDMO (Contract Development and Manufacturing Organization) business [2] Group 2: Financial Performance and Market Position - Heparin raw material revenue has shown continuous growth from 2016 to June 2019, further consolidating the company's market position [3] - The heparin preparation business has maintained high-speed growth, with active expansion into foreign markets, including the submission of applications for various heparin sodium injection products in Europe, the USA, and Brazil [3] Group 3: CDMO Business Development - The CDMO business has seen continuous growth driven by product research and development capabilities, industrialization capabilities, and global market capabilities, with numerous collaborations with well-known pharmaceutical companies [3] - Since 2016, the number of approved applications for generic drug products has been steadily increasing, expanding the product line to meet market demand [3] Group 4: Market Insights and Future Prospects - Currently, China's heparin usage accounts for only 5% of the global total, indicating significant future growth potential as the per capita usage is only one-tenth of that in European countries [4] - The market for low molecular weight heparin is broad, with applications in various medical fields, including orthopedics, cardiovascular, and reproductive health, highlighting its safety compared to other anticoagulants [4]

Financial Performance - Operating revenue for the first nine months reached CNY 1,827,963,329.80, a growth of 40.14% year-on-year[5] - Net profit attributable to shareholders increased by 34.11% to CNY 448,538,877.54 compared to the same period last year[5] - Basic earnings per share rose by 33.94% to CNY 0.6243[5] - The company's operating revenue for Q3 2019 was CNY 1,827,963,329.80, an increase of 40.14% compared to CNY 1,304,392,361.34 in the same period last year[11] - Total revenue for Q3 2019 reached ¥651,435,591.49, a 43.3% increase from ¥454,572,106.38 in Q3 2018[22] - Net profit for Q3 2019 was ¥159,334,917.16, representing a 48.5% increase compared to ¥107,347,586.63 in Q3 2018[23] - The company's operating revenue for Q3 2019 was CNY 599,946,441.37, a 59.5% increase from CNY 375,900,096.17 in Q3 2018[26] - The net profit for Q3 2019 reached CNY 143,350,075.44, compared to CNY 72,410,256.15 in the same period last year, representing a 97.8% year-over-year growth[27] Assets and Liabilities - Total assets increased by 33.34% to CNY 4,536,796,250.12 compared to the end of the previous year[5] - Total current assets increased to ¥3,920,240,959.17, up from ¥2,838,014,729.92, representing a growth of approximately 38.2% year-over-year[16] - Accounts receivable rose to CNY 393,262,214.51, reflecting a significant increase of 123.39% from CNY 176,045,699.29, primarily due to increased sales[10] - The company's inventory reached CNY 2,801,446,506.11, up 43.55% from CNY 1,951,505,576.93, driven by rising raw material prices and increased procurement[10] - Total liabilities amounted to ¥1,732,796,564.19, compared to ¥981,210,540.11, representing an increase of about 76.5%[18] - Owner's equity rose to ¥2,803,999,685.93 from ¥2,421,112,751.62, reflecting an increase of approximately 15.8%[18] - The total liabilities reached approximately $1.03 billion, with current liabilities accounting for approximately $1.00 billion[40] Cash Flow - Net cash flow from operating activities showed a significant decline, reaching -CNY 642,031,422.77, a decrease of 2,291.39% year-on-year[5] - The net cash flow from operating activities was negative CNY 642,031,422.77, a decline of 2,291.39% compared to negative CNY 26,847,588.96, mainly due to increased procurement costs[13] - Total cash inflow from operating activities was 1,838,549,897.36 RMB, up from 1,551,485,103.33 RMB year-over-year[30] - Cash outflow from operating activities increased to 2,480,581,320.13 RMB, compared to 1,578,332,692.29 RMB in the same period last year[30] - The net cash flow from investing activities was -211,951,974.30 RMB, a decrease from 265,133,061.37 RMB in the previous year[30] - Cash inflow from financing activities totaled 1,463,365,925.96 RMB, significantly higher than 537,938,391.43 RMB in the prior year[33] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,891[8] - The largest shareholder, Xie Juhua, holds 28.25% of the shares, totaling 202,971,019 shares[8] - Jiangsu Coastal Development Group Co., Ltd. holds 21.8% of the shares, totaling 156,652,248 shares[8] Research and Development - Research and development expenses increased to CNY 121,717,723.81, a rise of 43.30% compared to CNY 84,938,344.11, indicating a focus on expanding R&D capabilities[13] - Research and development expenses for Q3 2019 were ¥46,821,529.69, a 37.9% increase from ¥33,974,794.51 in Q3 2018[22] Other Income and Expenses - The company reported non-operating income of CNY 31,468.43 from tax refund[7] - The company received government subsidies, contributing to an increase in other income, which rose to CNY 7,804,144.63, a 112.87% increase from CNY 3,666,125.84[13] - The company's sales expenses for Q3 2019 were CNY 97,771,153.96, a 61.7% increase from CNY 60,444,059.95 in Q3 2018[26] - The financial expenses for Q3 2019 were CNY 8,736,167.18, compared to CNY 4,236,963.52 in Q3 2018, indicating a 106.0% increase[26]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,176,527,738.31, representing a 38.44% increase compared to CNY 849,820,254.96 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 289,203,960.38, up 27.34% from CNY 227,116,438.00 in the previous year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 279,944,994.95, reflecting a 30.13% increase from CNY 215,126,027.31 year-on-year[16]. - Basic earnings per share for the first half of 2019 increased by 65.21% to CNY 0.5234 compared to CNY 0.3168 in the same period last year[17]. - The total comprehensive income for the first half of 2019 was CNY 289,565,755.99, up from CNY 224,649,195.82 in the same period of 2018[132]. - The total operating profit for the first half of 2019 was CNY 260,182,228.34, an increase from CNY 164,619,709.96 in the same period of 2018, showcasing operational efficiency[130]. Cash Flow and Financial Position - The net cash flow from operating activities was negative CNY 345,240,349.01, a significant decrease compared to a positive CNY 1,891,149.01 in the same period last year, marking an 18,355.59% decline[16]. - Cash and cash equivalents increased by 33.23% to ¥579,302,831.21, accounting for 13.39% of total assets[42]. - Accounts receivable rose by 83.05% to ¥322,256,922.00, representing 7.45% of total assets due to increased sales[42]. - Inventory increased by 25.05% to ¥2,440,318,283.91, making up 56.4% of total assets, attributed to rising raw material prices and increased procurement[42]. - Short-term borrowings surged by 190.07% to ¥928,062,568.75, constituting 21.45% of total liabilities, due to increased bank loans[42]. - The total liabilities of the company reached CNY 1,688,425,970.42, up from CNY 981,210,540.11, which is an increase of about 72.0%[121]. Research and Development - The company’s research and development expenses increased by 46.96% to CNY 74,896,194.12, indicating a strong commitment to innovation[39]. - The company aims to strengthen its R&D in other pharmaceutical products while maintaining its leading position in the low molecular weight heparin market[22]. - The company is actively pursuing clinical trials for new products, with a clinical trial notification received from the National Medical Products Administration on June 17, 2019[37]. Market Position and Strategy - The company is the only domestic enterprise with three types of low molecular weight heparin preparations approved for production, achieving significant revenue growth in this sector[23]. - The company has established long-term stable partnerships with major heparin formulation companies such as Sanofi, Pfizer, and Sandoz, enhancing customer loyalty[25]. - The company has established a complete sales channel and operational experience in the U.S. market, with sterile injection products already being sold, marking a key growth point for future sales[23]. - The company has been recognized as a high-tech enterprise and has received multiple certifications, enhancing its competitive edge in the pharmaceutical industry[22]. Environmental Compliance - The total wastewater discharge from the API plant was 132,788.42 tons/year, with COD emissions of 6.592 tons/year and ammonia nitrogen emissions of 0.355 tons/year[85]. - The company has not experienced any environmental pollution incidents or exceeded emission standards during the reporting period[84]. - The wastewater from the API plant meets the Class III standard of the Comprehensive Wastewater Discharge Standard (GB8978-1996) before being treated at the municipal wastewater treatment plant[87]. Shareholder and Equity Information - The company reported a total share capital of 55,267.253 million shares after the recent stock changes, which included the issuance of 474,000 shares and the repurchase of 227,370 shares[105]. - Major shareholders, including the actual controllers, express confidence in the company's future and plan to hold shares long-term, with any reductions in holdings priced no lower than the issue price[59]. - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with a maximum of 25% transfer allowed annually during the tenure of directors and senior management[51]. Financial Reporting and Compliance - The company adheres to the accounting standards and ensures that its financial statements reflect a true and complete view of its financial status[169]. - The financial statements are prepared in accordance with the Accounting Standards for Business Enterprises No. 33, ensuring the elimination of significant internal transactions and balances[177]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[174].

Financial Performance - The company's operating revenue for 2018 reached ¥1,700,330,667.14, representing a 52.81% increase compared to ¥1,112,726,003.22 in 2017[20] - The net profit attributable to shareholders of the listed company was ¥424,549,136.66, a 35.11% increase from ¥314,222,399.37 in the previous year[20] - The total assets of the company increased by 26.26% to ¥3,402,323,291.73 from ¥2,694,760,477.54 in 2017[20] - The company's net cash flow from operating activities improved significantly to ¥62,368,493.94, compared to a negative cash flow of ¥234,586,486.85 in 2017, marking a 126.59% increase[20] - Basic earnings per share for 2018 increased by 25.74% to CNY 0.7694 compared to CNY 0.6119 in 2017[21] - The weighted average return on equity for 2018 was 19.12%, a slight increase of 0.05 percentage points from 19.07% in 2017[21] - The total operating income for 2018 was CNY 1.70 billion, with a significant contribution from heparin products[28] - Non-recurring gains for 2018 totaled CNY 13.38 million, compared to CNY 8.62 million in 2017[26] - The company reported a 12.4% year-on-year increase in revenue for the pharmaceutical manufacturing industry, with total revenue reaching 24,264.7 billion yuan in 2018[35] Market Position and Strategy - The company is recognized as a leading producer of heparin raw materials in China, holding a dominant market share[29] - The company has achieved a good reputation in the domestic low molecular weight heparin market, resulting in substantial revenue growth[29] - The company aims to enhance its global supply capabilities while focusing on high-quality pharmaceutical production[28] - The company has established long-term stable partnerships with major heparin formulation companies such as Sanofi, Pfizer, and Sandoz, enhancing customer loyalty[33] - The company utilizes a direct sales model for heparin raw materials, supplemented by distributors, to expand its international market presence[32] - The company has a robust customer base, including major global pharmaceutical companies like Pfizer and Sanofi, which enhances its market position and operational stability[43] - The company has developed a CDMO business model, providing comprehensive services for sterile injectable drug development and production, catering to both global and domestic pharmaceutical companies[41] Research and Development - The company’s R&D investment amounted to CNY 124,475,700, reflecting a year-on-year increase of 61.27%[55] - The company has two R&D centers, located in Nanjing and Chengdu, specializing in the development and industrialization of sterile injectables[89] - The company has multiple products in various stages of development, including 1,636.51 million RMB for an anticoagulant drug in the review stage in the US, and 1,032.69 million RMB for a muscle relaxant drug under review in both China and the US[98] - The company is actively pursuing new product development, with 10 new projects initiated in 2019, including antimicrobial and antitumor drugs[102] - The company has submitted applications for several products, including RD-014 and RD-2017-NF002, which are currently under technical review in China and the US[100] - The company has achieved significant progress in its R&D efforts, focusing on high-demand therapeutic areas such as oncology, anesthesia, and anticoagulation[99] Environmental Responsibility - The company is classified as a key pollutant discharge unit in Nanjing, with a chemical oxygen demand (COD) discharge concentration of 91 mg/L and an annual discharge of 6.2 tons[185] - The company operates one wastewater treatment plant with a daily processing capacity of approximately 400 tons, which is currently functioning normally[187] - The company has implemented a dual treatment system for exhaust gases, utilizing photocatalysis and biological filtration to reduce environmental pollution[187] - The company has established an emergency response plan for environmental incidents, which has been filed with the Nanjing High-tech Zone Environmental Protection Bureau[190] - The company has received multiple environmental approvals for construction projects, including a solvent workshop renovation project approved in June 2017[188] - The company has not experienced any environmental pollution incidents or exceeded discharge standards during the reporting period[185] Shareholder Relations and Corporate Governance - The company has a stable cash dividend policy aimed at providing reasonable returns to investors while ensuring sufficient funds for ongoing operations[129] - The company prioritizes cash dividends, distributing at least 10% of the available profit as cash dividends annually[130] - The board of directors must consider industry characteristics, development stages, and profitability when proposing profit distribution plans[132] - The company guarantees that its prospectus does not contain false records, misleading statements, or significant omissions, and it will bear legal responsibility for the accuracy and completeness of the prospectus[140] - The company will ensure that any profits gained from unfulfilled commitments will be returned to the company[144] - Major shareholders, including controlling shareholders Tang Yongqun and Xie Juhua, have committed to holding their shares long-term and will not reduce their holdings below the issue price for two years after the lock-up period[145] Risks and Challenges - The company faces industry policy risks due to increasing regulatory scrutiny in the pharmaceutical sector, necessitating proactive market development and cost control measures[125] - The company is exposed to product quality control risks, particularly in the heparin market, which requires adherence to strict cGMP standards and robust quality management systems[126] - The company recognizes the potential for market changes in the heparin sector due to patent expirations and new generic drug entries, which could impact its sales and partnerships[127] - The implementation of consistency evaluation policies is expected to enhance the overall quality standards in the pharmaceutical industry, leading to increased industry concentration[118] Capital Structure and Shareholder Equity - The total share capital increased from 42,350 million shares to 55,242.59 million shares after a capital increase of 12,705 million shares through a public reserve fund conversion[198] - The company’s total share capital after all adjustments is 55,242.59 million shares, with 51.52% being tradable shares[198] - The company’s share capital structure reflects a significant shift in ownership distribution post-capital increase[198] - The proportion of limited sale shares decreased from 85.01% to 48.48% after the capital increase[198]